(Q44334907)

2 December 2017

title

Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients (English)

1 reference

2 December 2017

1 reference

1 reference

Kelong Han

1

1 reference

2 December 2017

Robert Bies

2

1 reference

2 December 2017

Heather Johnson

3

1 reference

2 December 2017

Blair Capitano

4

1 reference

2 December 2017

Raman Venkataramanan

5

1 reference

2 December 2017

publication date

1 March 2011

1 reference

Clinical Pharmacokinetics

2 December 2017

published in

1 reference

2 December 2017

volume

50

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

201-214

1 reference

https://scigraph.springernature.com/pub.10.2165/11538690-000000000-00000

2 December 2017

exact match

0 references

cites work

Outbreak of invasive aspergillosis among renal transplant recipients

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Role of newer azoles in surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Interaction between voriconazole and tacrolimus in a kidney-transplanted patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole : a review of its use in the management of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Antifungal agents--clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Adverse reactions to voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Clinical pharmacokinetics of voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Relationship of blood level and susceptibility in voriconazole treatment of histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

The safety of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Voriconazole pharmacokinetics in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Postoperative visceral hypotension the common cause for gastrointestinal complications after cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Early changes of small intestine function in rats after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Cost-effectiveness of therapeutic drug monitoring: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538690-000000000-00000

Current and emerging azole antifungal agents

21 January 2018

1 reference

12 December 2020

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

1 reference

12 December 2020

Voriconazole: a new triazole antifungal agent

1 reference

12 December 2020

Cyclosporine: experience with therapeutic monitoring

1 reference

12 December 2020

Effects of surgery on the pharmacokinetic parameters of drugs

1 reference

12 December 2020

Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

1 reference

12 December 2020

10.2165/11538690-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

2 December 2017

1009161381

0 references

1 reference